Long-term maintenance of prognostic value of survivin and its relationship with p53 in T4 breast cancer patients

Experimental and Therapeutic Medicine

Volumn 1, Issue 1, 2010, Pages 59-64

  Ionta, Maria Teresa ^a   Perra, Maria Teresa ^a   Atzori, Francesco ^a   Maxia, Cristina ^a   Pusceddu, Valeria ^a   Demurtas, Paolo ^a   Deidda, Maria Cristina ^a   Piras, Franca ^a   Frau, Barbara ^a   Murtas, Daniela ^a   Minerba, Luigi ^a   Massidda, Bruno ^a   Sirgu, Paola ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Prognosis; Survivin; T4 breast cancer

Indexed keywords

ALKALINE PHOSPHATASE; BIOTIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; PROTEIN P53; STREPTAVIDIN; SURVIVIN; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY;

EID: 77955719282     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000010     Document Type: Article

References (25)

1. Ferlay J, Bray F, Pisani P and Parkin DM; GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Press, Lyon, 2004.
2. Dowsett M and Dunbier AK: Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14: 8019-8026, 2008.
3. Altieri DC: Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem 269: 3139-3142, 1994.
4. Altieri DC: Splicing of effector cell protease receptor-1 mRNA is modulated by an unusual retained intron. Biochemistry 33: 13848-13855, 1994.
5. Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000-5005, 2008.
6. Ambrosini G, Adida C and Altieri DC: A novel antiapoptosis gene, survivin expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
7. Adida C, Crotty PL, McGrath J, et al: Developmentary regulated expression of the novel cancer antiapoptosis gene survivin in human and mouse differentiation. Am J Pathol 152: 43-49, 1998.
8. Olie RA, Simões-Wüst AP, Baumann B, et al.: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60: 2805-2809, 2000.
9. Sah NK, Khan Z, Khan GJ and Bisen PS: Structural, functional and therapeutic biology of survivin. Cancer Lett 244: 164-171, 2006.
10. O'Driscoll L, Linehan R, Kennedy MS, et al: Lack of prognostic significance of survivin, survivin-ΔEx3, survivin-2B, galectin-3, bag-1, bax-α and MRP -1 mRNA s in breast cancer. Cancer Lett 201: 225-236, 2003.
11. Hinnis AR, Luckett JCA and Walker RA: Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 96: 639-645, 2007.
12. Tanaka K, Iwamoto S, Gon G, et al: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127-134, 2000.
13. Bertheau P, Espié M, Turpin E, et al: TP 53 status and response to chemotherapy in breast cancer. Pathobiology 75: 132-139, 2008.
14. Brennan DJ, Rexhepaj E, O'Brien SL, et al: Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 14: 2681-2689, 2008.
15. Hayward JL, Carbone PP,Heusen JC, et al: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292-298, 1977.
16. Sataloff DM, Mason BA, Prestipino AJ, et al: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180: 297-306, 1995.
17. Li F and Ling X: Survivin study: an update of 'what is the next wave'? J Cell Physiol 208: 476-486, 2006.
18. Dohi T, Beltrami E, Wall NR, Plescia J and Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114: 1117-1127, 2004.
19. Li XN, Shu Q, Su JM, et al: Differential expression of survivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol 33: 67-76, 2007.
20. Altieri DC and Marchisio PC: Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79: 1327-1333, 1999.
21. Kennedy SM, O'Driscoll L, Purcell R, et al: Prognostic importance of survivin in breast cancer. Br J Cancer 88: 1077-1083, 2003.
22. Ponnelle T, Chapusot C, Martin L, et al: Cellular localisation of survivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol 131: 504-510, 2005.
23. Xie D, Zeng YX, Wang HJ, et al: Expression of cytoplasmic and nuclear survivin in primary and secondary human glioblastoma. Br J Cancer 94: 108-114, 2006.
24. Piras F, Murtas D, Minerba L, et al: Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology 50: 835-842, 2007.
25. Mirza A, McGuirk M, Hockenberry TN, et al: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622, 2002.